Isis Pharmaceuticals (NASDAQ:ISIS): Closing price $21.66
On Thursday, Isis announced that it earned a $6-million payment from AstraZeneca linked with a continuation of the research collaboration aimed at discovering and developing novel antisense therapeutics for the treatment of cancer. Alongside the research collaboration, which includes three cancer targets, the firms are developing two antisense drugs, ISIS-AR and ISIS-STAT, discovered by Isis and licensed to AstraZeneca to treat cancer.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.